Brokers Offer Predictions for CNTX Q3 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – HC Wainwright issued their Q3 2025 earnings estimates for Context Therapeutics in a note issued to investors on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.05) EPS.

CNTX has been the topic of several other reports. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Friday. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Finally, JMP Securities assumed coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Trading Up 0.2 %

Shares of CNTX stock opened at $0.77 on Monday. The firm’s 50 day moving average is $0.85 and its 200-day moving average is $1.43. Context Therapeutics has a 1 year low of $0.64 and a 1 year high of $2.75. The firm has a market capitalization of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently made changes to their positions in the stock. MPM Bioimpact LLC bought a new stake in shares of Context Therapeutics during the fourth quarter worth $15,441,000. Blue Owl Capital Holdings LP increased its position in shares of Context Therapeutics by 17.5% during the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock worth $6,676,000 after acquiring an additional 946,638 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Context Therapeutics by 115.9% during the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock worth $4,204,000 after acquiring an additional 2,149,392 shares in the last quarter. Allostery Investments LP bought a new stake in shares of Context Therapeutics during the fourth quarter worth $998,000. Finally, Geode Capital Management LLC increased its position in shares of Context Therapeutics by 9.2% during the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after acquiring an additional 52,830 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.